|Bid||5.20 x 3200|
|Ask||5.21 x 1200|
|Day's Range||5.11 - 5.40|
|52 Week Range||4.68 - 9.42|
|Beta (3Y Monthly)||2.59|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 31, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.25|
Progenics (PGNX) delivered earnings and revenue surprises of 50.00% and 28.43%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
AZEDRA® (iobenguane I 131) Approved by U.S. Food and Drug Administration (FDA)AZEDRA U.S. Launch Progressing and AZEDRA Added to the NCCN Guidelines and Four CMS-Recognized Drug.
NEW YORK, Nov. 06, 2018 -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and.
Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, announced today that it will host a conference call and webcast to review the third quarter ended September 30, 2018 financial results on Thursday, November 8, 2018 at 8:30 a.m. ET. Forward looking statements are generally accompanied by words such as "anticipate," "believe," "plan," "could," "should," "estimate," "expect," "forecast," "outlook," "guidance," "intend," "may," "might," "will," "possible," "potential," "predict," "project," or other similar words, phrases or expressions.
NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced plans to advance I-131 1095, its PSMA-targeted therapeutic, into a Phase 2 clinical study. The multicenter, randomized, controlled trial will evaluate the efficacy and safety of 1095 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) who are PSMA-avid, chemotherapy naïve, and progressed on abiraterone.
Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that the Company’s pivotal trial of AZEDRA® (iobenguane I 131), the Company’s radiotherapeutic, has been published in The Journal of Nuclear Medicine. The study entitled, “Efficacy and Safety of High-Specific-Activity I-131 MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma,” reports the complete results of the pivotal study of AZEDRA. This trial was the largest multicenter, prospective trial to evaluate the safety and efficacy of any therapy in patients with pheochromocytoma and paraganglioma and formed the basis of AZEDRA’s approval by the U.S. Food and Drug Administration (FDA) in July 2018.
-PyL highly sensitive, 93-99%, in reliably detecting metastatic prostate cancer lesions and highly specific, 96-99%, in confirming the absence of pelvic lymph node disease-.
In the second quarter, Acadia Pharmaceuticals reported net revenues of $57.1 million compared to $30.5 million in Q2 2017. Acadia Pharmaceuticals’ revenue growth could boost the share price of the First Trust NYSE Arca Biotechnology Index Fund (FBT). Acadia Pharmaceuticals’ peers in the biopharmaceuticals market include Progenics Pharmaceuticals (PGNX), Sarepta Therapeutics (SRPT), and Amicus Therapeutics (FOLD).
I am going to run you through how I calculated the intrinsic value of Progenics Pharmaceuticals Inc (NASDAQ:PGNX) by estimating the company’s future cash flows and discounting them to their Read More...
Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that Mark R. Baker, Chief Executive Officer, will present at the Cantor Fitzgerald Global Healthcare Conference in New York City on Tuesday, October 2, 2018 at 11:30 a.m. Eastern Daylight Time.
Progenics Pharmaceuticals' (PGNX) shares down on disappointing results from phase III study evaluating imaging agent, 1404, for prostate cancer detection.
Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that AZEDRA® (iobenguane I 131), the Company’s radiotherapeutic, has been added to the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology for Neuroendocrine and Adrenal Tumors v 3.2018. NCCN Guidelines® are widely recognized and used as the standard for clinical policy in oncology by clinicians and payors. NCCN Guidelines have been updated with AZEDRA, the first and only FDA approved treatment of patients 12 and older with iobenguane scan positive, locally unresectable and metastatic pheochromocytoma or paraganglioma.
NEW YORK, NY / ACCESSWIRE / September 14, 2018 / Both AbbVie and Progenics had data results this week for Wall Street to absorb. While shares of AbbVie saw gains on its data for Upadacitinib, an investigational oral agent engineered by the company to selectively inhibit JAK1 and is being studied as a once-daily therapy in atopic dermatitis, shares of Progenics were in the red on missing one endpoint in its phase 3 clinical trial testing of its prostate cancer imaging agent, 1404.
NEW YORK, NY / ACCESSWIRE / September 13, 2018 / U.S. markets were mixed on Wednesday as technology shares declined, dragging the Nasdaq into the red. The Dow Jones Industrial Average climbed 0.11 percent ...
Check out the companies making headlines after the bell: Pivotal Software PVTL shares tumbled more than 20 percent in after-hours trading despite reporting second-quarter earnings numbers that beat on both the top and bottom line.
Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced top line data from its Phase 3 study of 1404, the Company’s prostate specific membrane antigen (PSMA)-targeted small molecule SPECT/CT imaging agent that is designed to visualize prostate cancer. The Phase 3 trial evaluated the specificity of 1404 imaging to identify patients without clinically significant prostate cancer and sensitivity to identify patients with clinically significant disease.
In August, the FDA approved Amicus Therapeutics’ (FOLD) Galafold for the treatment of adults with a confirmed diagnosis of Fabry disease along with an amenable galactosidase alpha gene variant. The FDA’s approval of Galafold was according to the accelerated approval process based on the decrease in KIC GL-3 (kidney interstitial capillary cell globotriaosylceramide) substrate. Studies estimate that more than 3,000 individuals in the United States have Fabry disease.
On September 10, Amicus Therapeutics (FOLD) announced the regulatory and clinical progress of its AT-GAA development program for Pompe disease. The company has met with the FDA to discuss the regulatory trajectory for AT-GAA, and the FDA has provided final written minutes of the meeting. Amicus Therapeutics has implemented the suggestions of the FDA and the European Medicines Agency for the study.
On September 11, Verastem (VSTM) stock closed at $9.17, which is ~13% below its 52-week high of $10.35 on September 4. On September 6, Verastem announced that the company completed dosing the first patient with duvelisib and venetoclax combination therapy for the multicenter phase 1/2 trial at the Dana-Farber Cancer Center. Verastem is evaluating the safety and efficacy of duvelisib and venetoclax combination therapy for the treatment of individuals with relapsed or refractory chronic lymphoblastic leukemia or small lymphocytic lymphoma.
On August 24, Invitae (NVTA) stock closed at $12.56, which represents a ~4.75% growth from its prior day’s close of $11.99. It hit its 52-week high of $12.75 on August 24. For the week ended August 24, Invitae stock closed at $12.56, which represents a ~23% rise from its prior week’s close of $10.21 on August 17. Invitae delivered solid growth in the second quarter of 2018 when it reported revenues of $37.3 million compared to $14.3 million in Q2 2017.
NEW YORK, Aug. 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The ...